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Author Correction: 
Aptamer‑mediated survivin RNAi 
enables 5‑fluorouracil to eliminate 
colorectal cancer stem cells
Hadi AlShamaileh, Tao Wang, Dongxi Xiang, Wang Yin, Phuong Ha‑Lien Tran, 
Roberto A. Barrero , Pei‑Zhuo Zhang, Yong Li, Lingxue Kong, Ke Liu, Shu‑Feng Zhou, 
Yingchun Hou, Sarah Shigdar & Wei Duan
Correction to: Scientific Reports https ://doi.org/10.1038/s4159 8-017-05859 -z, published online 19 July 2017
This Article contains an error in the order of panels of Figure 1. Panels a, b, c, d and e should appear in the order 
d, e, a, b, c. The correct Figure appears below as Figure 1.
Additionally, the panels in Figures 3 and 4 are missing labels. The correct Figures appear below as Figures 2 and 
3 respectively.
Finally, the Supplementary Information file contains a typographical error.
“The chimera structure features an asymmetric structure to facilitate recognition by an endogenous Dicer enzyme 
to cleave the chimera which results in the release of the expected 21-mer siRNA sequence [251] (Figure S1b).”
should read:
“The chimera structure features an asymmetric structure to facilitate recognition by an endogenous Dicer enzyme 




Scientific Reports |        (2020) 10:22191  | https://doi.org/10.1038/s41598-020-77490-4
www.nature.com/scientificreports/
Figure 1.  EpCAM aptamer-guided RNAi effectively silenced survivin. (a) Specificity and efficacy of 
EpCAMaptamer guided RNAi in knocking down survivin mRNA. Chimera or negative control chimera 
were incubated with HT-29 or HEK-2913T cells for 24 hours and the total RNA was extracted for qRT-PCR 
analysis of survivin mRNA levels. GAPDH was used as an internal control. (b, c) HT-29 Tumour-bearing mice 
were treated with 2 nmol/mouse of PEG-labelled chimera for 48 hours. The tumours were collected for RNA 
extraction followed by qRT-PCR analysis of survivin mRNA expression (b) and 5′RACE assay (c). (d) Effective 
downregulation of survivin protein via EpCAM aptamer-guided RNAi. Chimera or negative control chimera 
were incubated with HT-29 or HEK-2913T cells for 48 hours and the survivin protein levels were analyzed using 
Western blot analysis. β-actin was used as a loading control. (e) The bar graph shows the survivin protein levels 
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Figure 2.  Survivin knockdown in vivo enhances 5-FU-induced apoptosis in HT-29 tumour cells. (a) 
Representative images of TUNEL apoptosis assay on dissociated HT-29 xenograft tumours after in vivo 
treatment with chimera and 5-FU. NOD/SCID mice bearing HT-29 tumours (60  mm3) were treated 
intravenously with 3 injections of 2 nmol/mouse of chimera with or without 3 additional treatment of 30 mg/kg 
of 5-FU. Two days after the final treatment, tumours were dissociated by collagenase digestion and subjected to 
TUNEL apoptosis assay. (b) Percentage of apoptotic cells in treated tumours. Data shown are means ± SEM, n = 
3. ****p < 0.001. NS, no statistically significant difference.
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Figure 3.  Combined chimera and 5-FU treatments improves therapeutic outcome in HT-29 tumour-bearing 
mice. (a) The graph represents the tumour volume in mice in response to various treatments as indicated. (b) 
Survival rate of mice observed over the course of various treatments. Data shown are mean ± SEM, n = 4–5.
